Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Meridian Bioscience

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

Looking Into Meridian Bioscience's Return On Capital Employed

Looking Into Meridian Bioscience's Return On Capital Employed

According to Benzinga Pro, during Q2, Meridian Bioscience (NASDAQ:VIVO) earned $28.75 million, a 87.43% increase from the preceding quarter. Meridian Bioscience also posted a total of $111.23 million in sales, a 25.91% increase since Q1.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Meridian Bioscience: Q2 Earnings Insights

Meridian Bioscience (NASDAQ:VIVO) reported its Q2 earnings results on Friday, May 6, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Meridian Bioscience's Earnings: A Preview

Meridian Bioscience (NASDAQ:VIVO) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Meridian Bioscience will report an earnings per share (EPS) of $0.47.

Meridian Bioscience Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Meridian Bioscience (NASDAQ:VIVO) earned $15.34 million, a 130.43% increase from the preceding quarter. Meridian Bioscience also posted a total of $88.34 million in sales, a 15.93% increase since Q4.

Looking Into Meridian Bioscience's Return On Capital Employed

According to Benzinga Pro, during Q1, Meridian Bioscience (NASDAQ:VIVO) earned $15.34 million, a 130.43% increase from the preceding quarter. Meridian Bioscience also posted a total of $88.34 million in sales, a 15.93% increase since Q4.

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Meridian Bioscience's Shares Are Rising Today?

Why Meridian Bioscience's Shares Are Rising Today?

Meridian Bioscience Inc (NASDAQ: VIVO) has posted

Meridian Bioscience: Q1 Earnings Insights

Meridian Bioscience: Q1 Earnings Insights

Meridian Bioscience (NASDAQ:VIVO) reported its Q1 earnings results on Friday, February 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Earnings Preview: Meridian Bioscience

Earnings Preview: Meridian Bioscience

Meridian Bioscience (NASDAQ:VIVO) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Meridian Bioscience will likely report an Earnings Per Share (EPS) of $0.25.

Organisations

European Commission

PayPal Holdings

US Food and Drug Administration

American Airlines Group

Bristol Myers Squibb

Huntington Bancshares

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

331,975 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play